Eterna Therapeutics appoints Peter Cicala to Board of Directors

Ernexa Therapeutics Inc.

Appointed Feb 12, 2024, effective immediately; independent director under Nasdaq rules.
Serves on Audit, Compensation, and Nominating & Corporate Governance Committees.
Receives standard non-employee director compensation per 2023 proxy statement.
No material interest transactions or arrangements with other persons.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Peter Cicala

Director

ERNA · Ernexa Therapeutics Inc.

Effective: 2024-02-12
Filed: February 16, 2024, 6:59 PM ET

On February 12, 2024, and effective as of that date, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors (the “Board”) of Eterna Therapeutics Inc. (the “Company”) appointed Mr. Peter Cicala to the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter Cicala was appointed as Director at Ernexa Therapeutics Inc..

Action: appointed
Role: Director

Exact text from the filing

On February 12, 2024, and effective as of that date, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors (the “Board”) of Eterna Therapeutics Inc. (the “Company”) appointed Mr. Peter Cicala to the Board.

View on SEC.gov

Ernexa Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-008273

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.